‘It’s not an easy pill to take’: The first highly anticipated GLP-1 pill is here, but physicians aren’t sure it has the ...

When Mike Doustdar started as a summer employee making copies at Novo Nordisk—a teenager living in Austria after fleeing unrest in his home country of Iran at 12—he never imagined he would remain at ...

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and ...

Feb 10 (Reuters) - Novo Nordisk's U.S. patent lawsuit against Hims & Hers, filed on Monday, ‌marks ​a new front in the Danish ...

Eli Lilly ( LLY 1.41%) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit ...

Healthcare experts answer the most common questions about TrumpRx, plus who this new government portal is best for.

The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing ...

Hims & Hers says it will stop selling a low-cost copy of a new weight-loss pill made by Novo Nordisk, after federal officials raised concerns that the product may violate drug laws.

Novo Nordisk announced this morning it filed a lawsuit against Hims for infringing on its semaglutide patent. The drugmaker cited the FDA's announcement and warnings from organizations including the ...

The FDA’s latest letter takes aim at a Wegovy pill TV ad, arguing the ad was false or misleading, and that it positioned the pill as a “solution to broader life challenges.” ...

Novo Nordisk (NVO) stock is in focus as the FDA accuses the company of adding mileading cliams in a TV advertisement for its ...